Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol.14, Issue 20s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Harnessing AI to Revolutionize Antibiotic Discovery

Sakshi[1], Arindam Adhikary[2*], Inkashaf Alam[3], Kanisheka Sharma[4]

[1]Department of Medical Laboratory Sciences, USAHS, Rayat Bahra University, Mohali, India.

Email ID : singhsakshi20012001@gmail.com

[2*]Department of Medical Laboratory Sciences, Rayat Bahra University, Mohali, India.

[3]Department of Medical Laboratory Technology UIAHS Chandigarh University Mohali India.

Email.id inkashafalam2@gmail.com

[4]Department of Medical Laboratory Sciences, Rayat Bahra University, Mohali, India.

[*]**Corresponding Author:**
Arindam Adhikary

.Cite this paper as Sakshi, Arindam Adhikary, Inkashaf Alam, Kanisheka Sharma (2025) Harnessing AI to Revolutionize Antibiotic Discovery..Journal of Neonatal Surgery, 14, (20s) 1024-1028

ABSTRACT

The threats posed by antimicrobial resistance (AMR) being rapidly spread to all parts of the world are undermining the effectiveness of all the available classes of antibiotics and thus a new system of detecting the drug efficiently and effectively is required. The curve of multidrug resistance among pathogenic organisms is increasing at a rate exceeding the paradigms of conventional drug discovery that are both time- and cost-consuming. Over the last few years, the pharmaceutical industry has experienced a paradigm shift, and this is because machine learning (ML) and deep learning (DL) have the capacity to question large chemical libraries, predict antimicrobial activity, and design new antibacterial agents rationally. Modern antibiotics are not only effective in averting existing resistance types, but also in preventing emergence of new resistances. In addition, ML and AI methods are utilized in developing drugs based on infectious disease studies to optimize the representations of compounds using quantitative structure-activity relationship (QSAR) models, optimized descriptors, and neural networks. Deep-learning generative systems and reinforcement-learning systems are also used to design new bioactive molecules to combat resistance mechanisms. Those projects, like BacEffluxPred that categorize efflux pumps that initiate antibiotic resistance, complement genomic surveillance and, at the broader level, define important drug targets. Moreover, machine-learning-based drug discovery platforms combine high-content imaging with classification algorithms to clarify and predict antimicrobial mechanisms of action and in addition to discovering the suboptimally active, which is otherwise undiscoverable. The systems will show a significant improvement compared to the conventional computing resources, decreasing the time required to conduct an experiment and enhancing the reproducibility and efficiency of the results gained in the course of preclinical triage. Altogether, the artificially intelligent methods of antibiotic discovery form a new paradigm with regard to pharmaceutical development and microbiological research. Artificial intelligence has the potential to comprehend current global issues connected with antimicrobial resistance, as the synthesis of anticipatory capability at an expedited reaction and within a profound mechanistic coverage. This highlights how the authors have been determined to combine AI with empirical microbiology in order to develop next generation antibiotics as well as revamp therapeutic innovation

Keywords: *QSAR modeling, artificial intelligence (AI), machine learning, deep learning, and antibiotic discovery Antimicrobial Resistance (AMR) and artificial intelligence..*

1. INTRODUCTION

The Clinical significance of microorganisms Antimicrobial resistance of microorganisms that are of clinical significance undermines the effectiveness of current antibiotics, and hence it has led to a significantly high mortality rate in the world [1]. The Centers for Disease Control and Prevention (CDC) confirm that in the United States, annually, about 2.8 million infections are carried out by antibiotic-resistant bacteria [2]. Exposure to antibiotics has already been shown to significantly destabilize the gut microbiome, decreasing the diversity of species and promoting the evolution and spread of antimicrobial resistance genes, which ironically may be an indication of a possible remedial approach [3]. The demand for the novel antibiotics supports the demand for innovative approaches to antibiotic discovery. Clinical trial antibiotics have similarities to current medications and widely used [4]. AI is the term for the means used by computers to replicate intelligent human behaviour. The methods used in artificial intelligence are typically divided into two major categories: Machine

Learning and Deep Learning. ML is one particular field of AI that utilizes computer science, mathematics and statistical techniques to improve machine performance via experience. DL specializes in applying neural networks for examining huge datasets,

thereby increasing machine learning. This domain is much more specialized than standard machine learning, and it employs artificial neural networks, which contain several layers, to handle complicated medical imaging challenges. AI is changing the way drugs are discovered and developed by making it easier to search through huge virtual chemical regions and speeding up the process of finding new molecules that could be useful for treating diseases. The embeddedness of the computational approaches to the accelerated drug development has spawned considerable breakthroughs in the rational design of bioactive compounds that exhibit activity in animal models. This advancement implies that the use of computer-aided methods can produce preclinical antibiotic nominees [5][6]. The recent years have seen the discovery of a small-molecule antibiotic active against a range of bacterial infections, and independent of docking or affinity estimation [7]. This paper will examine how artificial intelligence will be applied to the design of 2 major categories of bioactive compounds, which are small-molecule antibiotics and antimicrobial peptides (AMPs). Fig. 1 depicts a hierarchical model that involves deep learning, machine learning, and an overarching strategy of artificial intelligence.



Fig.1: Association between Artificial Intelligence, Machine Learning, and Deep Learning.

2. PROCEDURES FOR OPTIMIZING COMPOUND REPRESENTATION

For almost 50 years, researchers have been trying to find the most accurate quantitative structure-activity relationships (QSAR) measurements [8]. The objective of employing computational models of therapeutic prospects was to forecast their characteristics, enabling researchers to computationally evaluate the activity of newly synthesized molecules, thus circumventing the inefficient generation and evaluation of ineffective compounds. The challenge of encoding chemical or biological data for computational model application constitutes a significant research area in its own right. Subsequent studies aimed to optimize information density across minimal dimensions by consolidating descriptors through the integration of experimental data[9].Different machine learning techniques and methods, such as traditional dimensionality reduction methods like principal component analysis (PCA) and singular value decomposition, as well as feature selection methods like $\chi2$ statistical tests or shared data estimation, have been combined in the search for more clear and useful representations. Recurrent neural networks (RNNs) can be used for signal processing and natural language processing (NLP). RNNs were recently changed so that they can work with SMILES representations, which are just strings of letters that describe the structures of chemical species. Studies indicate that generative neural networks equipped with long short-term memory (LSTM) can learn from SMILES representations of existing pharmaceuticals and subsequently generate novel compounds [10]. Reinforcement learning and RNNs have been used together to automatically make an embedded representation of medications using their SMILES representations. Machine learning is useful for predicting antimicrobial activity, predicting antimicrobial resistance, and finding new antibiotics.



Fig.2: Machine Learning contributes to Antimicrobial activity.

3. AMR PREDICTION

Antibiotics are different from other treatments because they work on living things that can become resistant. AMR is going to get worse, which is something that most other areas of drug development don't have to worry about. In a similar way, computational antibiotic discovery has its own set of applied ML issues that come up because we need to keep an eye on how antimicrobial resistance develops, works, and changes. A significant challenge within AMR biology is the identification of efflux pumps transport proteins that expel a wide range of substrates, including antibiotics, from the bacterial cell. Such efflux systems play a major role. They can minimize intracellular drug and broad-spectrum antibiotic resistance, and enable bacteria to survive many drug classes simultaneously. Innovations in DNA sequencing have resulted in the identification of several efflux pump proteins. However, discriminating between non-ARE and antibiotic-resistant efflux proteins remains challenging. In order to fill this gap, BacEffluxPred was created as a two-level prediction system that uses Support Vector Machines (SVMs) and machine learning to correctly differentiate between ARE proteins and non-specific efflux to determine which proteins belong to which families.[11]. Data from efflux pumps, which are involved in resistance in many types of bacteria, could be simply and quickly entered into BacEffluxPred. The program helps the researcher quickly find new ARE proteins, understand their functions, and select which to focus on in the development of drugs or therapeutic treatment by implementing this complex classification. Combining genomic surveillance with AI-powered prediction models is making it possible to find AMR earlier, learn more about how it works, and better manage it across a wide range of microbial pathogens.

4. GENERATIVE DL FOR ANTIBIOTIC DISCOVERY

Generative deep learning (DL) methods are very important for finding new antibiotics using computers. LatentGAN is a good example of a de novo generative approach. It combines an autoencoder with a GAN to make molecular design better. The first step in this method is to use a pretrained heteroencoder to turn molecular structures into n-dimensional latent vectors [12]. Instead of training the GAN on SMILES strings, it is then trained directly on these latent vectors. This enables the model to sample just significant molecular representations and helps prevent chemical language issues. When trained on ChEMBL datasets, LatentGAN managed to produce novel drug-like molecules with structures that were different from existing actives but similar to them after being trained on datasets that utilized the specificity of specific targets, such as EGFR, HTR1A, and S1PR1. It was thought that many of these compounds would work against their biological targets. These results show that LatentGAN is promising and useful tool for developing new medications and antibiotics. Lastly, generative deep learning approaches and particularly, models based on GANs and autoencoders, such as LatentGAN offers effective, flexible and innovative methods of identifying novel antibiotic options and accelerating the development of novel treatments.

5. ANTIMICROBIAL ACTIVITY PREDICTION

Machine learning is used to develop antibiotics and determine their effectiveness as bacteria killers. Using chemical fragments, molecular descriptors, and antimicrobial peptides (AMPs) as learning inputs, researchers have developed a variety of machine learning models over the last ten years to address the QSAR challenge and develop new antibiotics [13]. Two classic methods, multinomial logistic regression and Support Vector Machines have been used to sort chemical fragments, measure AMP properties, and generate so-called functional molecular component vocabularies that can be mixed and matched to propose new drug candidates [14]. Phenotypic drug discovery (PDD) is different from more traditional machine learning in that it does not use molecular representation. Instead of looking at a compound's chemical structure, PDD looks at how it affects target organisms. An important example is the semi-automated Bacterial Phenotypic Fingerprint (BPF) platform, which works with multiparametric high-content screening (HCS) and a strong ML analysis pipeline [15]. It is possible to accurately predict antimicrobial activity and identify modes of action (MoA) using machine-learning techniques (random forests with cellular imaging data, no complex chemical descriptions required). By making sure that chemical modification does not remove those intended MoAs, this method will improve the optimization of structure-activity relationships (SAR) and enable identification of weak antibacterial hits that could otherwise be missed during a typical screen. By examining the way drug compounds interact with pathogens rather than just comparing their molecular properties, this technique may also be helpful in discovering novel medicines.

6. THE FUTURE OF THE ANTIBIOTICS-DRIVING-MACHINE-LEARNING DEVELOPMENT.

Machine learning (ML) is set to have a significant impact on the further approach toward antibiotic development. The ML-based models can expand the search of chemical space by combining chemical, genomic, and phenotypic data and discovering new therapeutic targets and molecular structures, thus improving the computational methods. Deep-learning models that may be used to generate de novo, realistic molecules that may escape modern resistance are the generative adversarial networks (GANs), autoencoders, and reinforcement-learning models. Genomic surveillance that involves artificial intelligence will aid in the determination of the trends of antimicrobial-resistance (AMR) over time and consequently guide the judicious design of antibiotics with lasting effect. Such advances will require strong interdisciplinary co-operation between computational scientists and experimentalists, as well as increased access to data repositories and reproducible models, according to the current development in research. On the whole, it can be stated that ML-based research has the potential to hasten preclinical portfolios at a lower cost, and it will also broaden the antibiotic pipeline that is being increasingly required to address the growing global menace of drug-resistant pathogens.

7. CONCLUSION

The rapid disease burden of antimicrobial resistance (AMR) requires new methods of antibiotics discovery to be developed at a faster pace. The traditional approaches are naturally slow and resource based making them insufficient to face the quick evolution rate of the pathogenic organisms. This article demonstrates how artificial intelligence (AI), in this case machine learning (ML) and deep learning (DL), can be used to transform the current state of antibiotic research. Computer-based models powered by AI have a significant impact on predictive accuracy of antimicrobial action, refolding molecule representations, and immediate assessments of drug-likeness and toxicity, which reduce the number of experimental failures. Reinforcement learning and LatentGAN are examples of generative methods, which allow researchers to come up with completely new molecular scaffolds with high predicted bioactivity, and therefore, opens up chemical space to methods which are not accessible to traditional methods. In addition, AI helps to gain more insights and predict the development of bacterial resistance to antibiotics. The article provides an example of the computational tool, BacEffluxPred, which allows a researcher to classify proteins that are involved in efflux pumps relative to antimicrobial resistance with high accuracy, thus enabling the formulation of diagnostic assays to identify resistant infections and the construction of treatment-specific therapeutic interventions. The application of machine-learning algorithms in drug discovery to develop antibiotics is used as an addition to the development of antibiotics as it provides the modern means of cellular imaging and advanced classification techniques, which clarifies the mechanism of action and can identify the slightest changes in the reaction of bacteria. Lastly, the combination of artificial intelligence with chemical, microbiological and pharmaceutical development, pipelines, is expected to potentially create a new decision in terms of accuracy, throughput and innovative treatment plans. The competency of artificial intelligence in the context ofiance glass, i.e., its ability, should be understood way beyond an adjunct effectively a paradigmatic switch towards a data-driven, predictive, and automatic system of designing antibiotics. With the ongoing evolution of computational modeling in the next few years, artificial intelligence is set to be at the forefront of ensuring the global crisis of antimicrobial resistance is resolved, and at the same time, it will serve as the platform on which the next generation of effective, safe, and environmentally sustainable antimicrobial agent can be designed

REFERENCES

[1] D. M. P. De Oliveira et al., “Antimicrobial resistance in ESKAPE pathogens,” Clin. Microbiol. Rev., vol. 33, no. 3, 2020, doi: 10.1128/CMR.00181-19;PAGE:STRING:ARTICLE/CHAPTER.

[2] M. Craig, “CDC’s Antibiotic Resistance Threats Report, 2019 EXTENDED SPECTRUM β-LACTAMASE (ESBL)-PRODUCING ENTEROBACTERIACEAE,” 2019.

[3] K. R. Chng et al., “Metagenome-wide association analysis identifies microbial determinants of post-antibiotic ecological recovery in the gut,” Nat. Ecol. Evol., vol. 4, no. 9, pp. 1256–1267, Sep. 2020, doi: 10.1038/S41559-020-1236-0;TECHMETA.

[4] J. A. DiMasi, H. G. Grabowski, and R. W. Hansen, “Innovation in the pharmaceutical industry: New estimates of R&D costs,” J. Health Econ., vol. 47, pp. 20–33, May 2016, doi: 10.1016/J.JHEALECO.2016.01.012.

[5] M. D. T. Torres and C. de la Fuente-Nunez, “Toward computer-made artificial antibiotics,” Curr. Opin. Microbiol., vol. 51, pp. 30–38, Oct. 2019, doi: 10.1016/J.MIB.2019.03.004.

[6] W. F. Porto et al., “In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design,” Nat. Commun. 2018 91, vol. 9, no. 1, pp. 1490-, Apr. 2018, doi: 10.1038/s41467-018-03746-3.

[7] J. M. Stokes et al., “A Deep Learning Approach to Antibiotic Discovery,” Cell, vol. 180, no. 4, pp. 688-702.e13, Feb. 2020, doi: 10.1016/j.cell.2020.01.021.

[8] A. Cherkasov et al., “QSAR Modeling: Where Have You Been? Where Are You Going To?,” J. Med. Chem., vol. 57, no. 12, pp. 4977–5010, Jun. 2014, doi: 10.1021/JM4004285.

[9] G. J. P. Van Westen, R. F. Swier, J. K. Wegner, A. P. I. Jzerman, H. W. T. Van Vlijmen, and A. Bender, “Benchmarking of protein descriptor sets in proteochemometric modeling (part 1): comparative study of 13 amino acid descriptor sets,” J. Cheminformatics 2013 51, vol. 5, no. 1, pp. 41-, Sep. 2013, doi: 10.1186/1758-2946-5-41.

[10] M. Awale, F. Sirockin, N. Stiefl, and J. L. Reymond, “Drug Analogs from Fragment-Based Long Short-Term Memory Generative Neural Networks,” J. Chem. Inf. Model., vol. 59, no. 4, pp. 1347–1356, Apr. 2019, doi: 10.1021/ACS.JCIM.8B00902.

[11] D. Pandey, B. Kumari, N. Singhal, and M. Kumar, “BacEffluxPred: A two-tier system to predict and categorize bacterial efflux mediated antibiotic resistance proteins,” Sci. Reports 2020 101, vol. 10, no. 1, pp. 9287-, Jun. 2020, doi: 10.1038/s41598-020-65981-3.

[12] M. Popova, O. Isayev, and A. Tropsha, “Deep reinforcement learning for de novo drug design,” Sci. Adv., vol. 4, no. 7, Jul. 2018, doi: 10.1126/SCIADV.AAP7885.

[13] J. D. Durrant and R. E. Amaro, “Machine-learning techniques applied to antibacterial drug discovery,” Chem. Biol. Drug Des., vol. 85, no. 1, pp. 14–21, Jan. 2015, doi: 10.1111/CBDD.12423;WGROUP:STRING:PUBLICATION.

[14] R. A. Mansbach et al., “Machine Learning Algorithm Identifies an Antibiotic Vocabulary for Permeating Gram-Negative Bacteria,” J. Chem. Inf. Model., vol. 60, no. 6, pp. 2838–2847, Jun. 2020, doi: 10.1021/ACS.JCIM.0C00352.

[15] S. Zoffmann et al., “Machine learning-powered antibiotics phenotypic drug discovery,” Sci. Reports 2019 91, vol. 9, no. 1, pp. 5013-, Mar. 2019, doi: 10.1038/s41598-019-39387-9.

[16] Chan HCS, Shan H, Dahoun T, Vogel H, Yuan S. Advancing drug discovery via artificial intelligence. Trends Pharmacol Sci. 2019;40(8):592-604.

[17]. Mak K-K, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today. 2019;24(3):773-780.

[18] Hinton GE, Krizhevsky A, Wang SD. Transforming Auto-Encoders. Berlin, Heidelberg, Germany: Springer; 2011

[19] Becker G, Bolbos R, Costes N, Redoute J, Newman-Tancredi A, Zimmer L. Selective serotonin 5-HT1A receptor biased agonists elicit distinct brain activation patterns: a pharmacoMRI study. Sci Rep. 2016;6:26633.

[20] Downey D, Dutta A, McKie S, et al. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate. Eur Neuropsychopharmacol. 2016;26(6):994-1003.

[21] von Pföstl V, Li J, Zaldivar D, et al. Effects of lactate on the early visual cortex of non-human primates, investigated by pharmaco-MRI and neurochemical analysis. Neuroimage. 2012;61(1):98-105.